Basics Atossa Therapeutics, Inc. Atossa Genetics Inc mainly focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. IPO Date: November 8, 2012 Sector: Healthcare Industry: Biotech Market Cap: $101.79M Activated in VL: True Average Daily Range Avg Daily Range: $0.09 | 4.36% Avg Daily Range (30 D): $0.02 | 2.05% Avg Daily Range (90 D): $0.03 | 3.16% Institutional Daily Volume Avg Daily Volume: 1.73M Avg Daily Volume (30 D): .81M Avg Daily Volume (90 D): .7M Trade Size Avg Trade Size (Sh.): 365 Avg Trade Size (Sh.) (30 D): 351 Avg Trade Size (Sh.) (90 D): 301 Institutional Trades Total Inst.Trades: 168 Avg Inst. Trade: $2.14M Avg Inst. Trade (30 D): $3.98M Avg Inst. Trade (90 D): $3.98M Avg Inst. Trade Volume: .6M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $5.33M Avg Closing Trade (30 D): $9.36M Avg Closing Trade (90 D): $9.36M Avg Closing Volume: 1.6M     News Aug 28, 2025 @ 12:30 PM Atossa Therapeutics CEO to Discuss Clinical Progre... Source: Prnewswire Oct 14, 2024 @ 9:08 PM Atossa Therapeutics to Present at the 2024 Maxim H... Source: N/A Jun 28, 2024 @ 12:30 PM Atossa Therapeutics Announces Updated Protocol for... Source: Atossa Therapeutics, Inc. Jun 25, 2024 @ 1:40 PM Are Medical Stocks Lagging Alvotech (ALVO) This Y... Source: Zacks Equity Research Jun 17, 2024 @ 12:30 PM Atossa Set to Join Russell 3000® Index Effectiv... Source: Atossa Therapeutics, Inc. Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.23 $-.07 $-.05 Diluted EPS $-.23 $-.07 $-.05 Revenue $ M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -28.72M $ -8.42M $ -6.72M Operating Income / Loss $ -29.99M $ -9.04M $ -7.41M Cost of Revenue $ $ $ Net Cash Flow $ -8.44M $ M $ M PE Ratio     Splits Apr 20, 2018:   1:12 Aug 26, 2016:   1:15